MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory ...

Proof-of-concept study underway for investigational oral therapy in Fragile X syndrome; top-line data from Phase 2 expected in 2027 FOSTER CITY, Calif., December 01, 2025--(BUSINESS WIRE)--Mirum ...

Investing.com -- Medirom Healthcare Technologies Inc. (NASDAQ:MRM) stock surged 22% in premarket trading Thursday after its subsidiary MOTHER Labs announced approval of a private placement of new ...

Microsoft is enabling threshold-based auto-archiving by default in Exchange Online to prevent email flow issues caused by mailboxes filling up faster than expected. While users can also configure ...

(RTTNews) - Several small-cap names posted sharp gains in Thursday's after-hours session, driven by fresh corporate updates, clinical developments, and strategic pivots. Below are five stocks that ...

This article describes the analysis of an LC-MS/MS method for over 600 pesticides and mycotoxins in a single injection using a rapid MRM acquisition rate approach on the SCIEX 7500+ system. Good data ...

MH002 is aimed at treating those with mild-to-moderate ulcerative colitis. Credit: Jo Panuwat D/Shutterstock.com. Belgium’s MRM Health has concluded a Series B funding round, raising €55m ($64m) to ...

Funding to support Phase 2b trial with MRM Health’s lead program MH002 in ulcerative colitis and advance two additional programs to IND approval Strategic partnership with Biocodex in biotherapeutics ...

Git isn’t hard to learn. Moreover, with a Git GUI such as Atlassian’s Sourcetree, and a SaaS code repository such as Bitbucket, mastery of the industry’s most powerful version control tools is within ...

What Happened: The Japanese healthcare technology company announced it will install World ID verification devices called “Orbs” across approximately 100 of its Re.Ra.Ku relaxation salons by December ...